.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX10_Concizumab.Concizumab .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02B_VitaminKAndOtherHemostatics.B02BX10_Concizumab.Concizumab| name: | Concizumab | |
| ATC code: | B02BX10 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 0.25 | mg |
| volume of distribution: | 4.8 | L |
| clearance: | 0.09 | L/h |
| other parameters in model implementation | ||
Concizumab is a humanized monoclonal antibody that inhibits tissue factor pathway inhibitor (TFPI) and is developed for the treatment of hemophilia A and B with or without inhibitors. It is under clinical investigation and not yet widely approved or marketed.
Pharmacokinetic parameters were assessed in healthy subjects, adolescents, and patients with hemophilia A and B. Key phase 1/2/3 studies indicate subcutaneous administration with dose proportional increases in exposure.